Genprex

Videos

Genprex Participates in Noble Capital Markets’ C-Suite Interview Series

Genprex participates in Noble Capital Markets’ C-Suite Interview Series, presented by Channelchek, led by Noble Capital Markets Biotechnology Analyst Ahu Demir, Ph.D.

Learn More

Genprex’s CEO Appears on the Big Biz Show for a Second Time

Genprex’s Chairman and Chief Executive Officer, Rodney Varner, participates in a live interview with the “Big Biz Show” for a second time, providing details on its lead drug candidate for NSCLC, its diabetes gene therapy and what lies ahead in the next 18 months in the midst of COVID-19.

Learn More

Genprex reveals slew of recent milestones as it plans for upcoming clinical trials

Genprex, Inc. (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive’s Christine Corrado about the Texas-based biotechnology company’s most recent updates. Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as Oncoprex. What’s more, its ramping up the production of its drug for upcoming clinical trials, and the company has joined the Russell 3000 index.

Learn More

Big Biz Show with Genprex’s CEO, Rodney Varner – Part 2

Genprex’s Chairman and Chief Executive Officer, Rodney Varner, participates in a live interview with the “Big Biz Show,” an emmy-award winning nationally syndicated TV and radio show to discuss the company’s gene therapy technologies.

Learn More

Big Biz Show with Genprex’s CEO, Rodney Varner – Part 1

Genprex’s Chairman and Chief Executive Officer, Rodney Varner, participates in a live interview with the “Big Biz Show,” an emmy-award winning nationally syndicated TV and radio show to discuss the company’s gene therapy technologies.

Learn More

Genprex forms global licensing deal with MD Anderson for its cancer drug Oncoprex

Genprex, Inc. (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the group has been awarded a worldwide license, allowing it to use lead candidate Oncoprex to treat cancer in combination with a range of immunotherapies.

Learn More

Genprex makes key hires to its board and executive team

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the gene therapy group has made a few key hires despite the economic downturn due to the coronavirus.

Learn More

Genprex’s newly licensed type 1 diabetes gene therapy’s potential explained by scientist

Dr. George Gittes, Professor of Surgery at the Children’s Hospital of Pittsburgh, explains how and why he began working on the diabetes gene therapy licensed by Genprex.

Learn More

Genprex sees newly licensed diabetes gene therapy as an ‘opportunity we couldn’t pass up’

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based biotech has signed a licensing agreement with the University of Pittsburgh for a diabetes gene therapy that could have the potential to treat Type 1 and Type 2 diabetes.

Learn More

UPMC Children’s Hospital Researchers Working On ‘Groundbreaking’ Procedure To Cure Diabetes

Thirty million Americans are living with diabetes and hoping someday to be cured. That day could come sooner than expected, thanks to a team of researchers at UPMC Children’s Hospital of Pittsburgh.

Learn More